Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma

Abstract Background There is continued debate regarding the optimal combinations of radiation therapy and chemotherapy in the preoperative treatment of locally advanced rectal adenocarcinomas. We report our single-institution experience of feasibility and early oncologic outcomes of short-course pre...

Full description

Bibliographic Details
Main Authors: Angela Y. Jia, Amol Narang, Bashar Safar, Atif Zaheer, Adrian Murphy, Nilofer S. Azad, Susan Gearhart, Sandy Fang, Jonathan Efron, Tam Warczynski, Amy Hacker-Prietz, Jeffrey Meyer
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Radiation Oncology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13014-019-1358-1
id doaj-6b3dd154f5e34c41a74fac0b7d0df4a5
record_format Article
spelling doaj-6b3dd154f5e34c41a74fac0b7d0df4a52020-11-25T03:54:23ZengBMCRadiation Oncology1748-717X2019-08-011411610.1186/s13014-019-1358-1Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinomaAngela Y. Jia0Amol Narang1Bashar Safar2Atif Zaheer3Adrian Murphy4Nilofer S. Azad5Susan Gearhart6Sandy Fang7Jonathan Efron8Tam Warczynski9Amy Hacker-Prietz10Jeffrey Meyer11Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of MedicineDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of MedicineDepartment of Surgery, Johns Hopkins University School of MedicineDepartment of Radiology and Radiological Science, Johns Hopkins University School of MedicineDepartment of Oncology, Johns Hopkins University School of MedicineDepartment of Oncology, Johns Hopkins University School of MedicineDepartment of Surgery, Johns Hopkins University School of MedicineDepartment of Surgery, Johns Hopkins University School of MedicineDepartment of Surgery, Johns Hopkins University School of MedicineDepartment of Surgery, Johns Hopkins University School of MedicineDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of MedicineDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of MedicineAbstract Background There is continued debate regarding the optimal combinations of radiation therapy and chemotherapy in the preoperative treatment of locally advanced rectal adenocarcinomas. We report our single-institution experience of feasibility and early oncologic outcomes of short-course preoperative radiation therapy (5 Gy X 5 fractions) followed by consolidation neoadjuvant chemotherapy. Methods We reviewed the records of 26 patients with locally advanced rectal adenocarcinoma. All patients underwent short course radiotherapy (5 Gy X 5 fractions) followed by chemotherapy [either modified infusional and bolus 5-fluorouracail and oxalipatin (mFOLFOX6) or capecitabine and oxaliplatin] prior to consideration for surgery. A full course of chemotherapy was defined as at least 8 weeks of chemotherapy. Results There were five clinical (c) T2, 16 cT3, and five cT4 rectal tumors, with 88% cN+. Twenty-five patients received a median of 4 cycles (range 3 to 8) of mFOLFOX6 (with one cycle defined as a two-week period); one patient received 3 cycles of capecitabine and oxaliplatin. All patients completed SCRT; 81% completed the full course of neoadjuvant chemotherapy with 19% requiring dose reductions in chemotherapy, most commonly due to neuropathy. Nineteen patients underwent post-treatment endoscopic evaluation, and nine patients were noted to achieve a complete clinical response (CCR). Six of the nine patients who achieved CCR opted for a non-operative approach of watch-and-wait. Twenty patients underwent surgical resection; pathologic complete response was observed in seven (35%) of these twenty. The main radiation-associated toxicity was proctitis with CTCAE Grade 2 proctitis observed in seven patients (27%). Post-operative Clavien-Dindo Grade 3 complications within 30 days of surgery were identified in six patients (30%), with no Grade 4 or 5 adverse events. Median length of hospital stay was 4.5 days (range 2–16 days); three patients were readmitted within a 30 day period. Conclusions Short course preoperative radiotherapy followed by neoadjuvant chemotherapy was well-tolerated and achieved oncologic outcomes that compare favorably with short-course radiation therapy alone or long-course chemoradiotherapy. This regimen is associated with high rates of clinical and pathologic complete response.http://link.springer.com/article/10.1186/s13014-019-1358-1Rectal cancerShort-course chemoradiotherapyWatch and wait
collection DOAJ
language English
format Article
sources DOAJ
author Angela Y. Jia
Amol Narang
Bashar Safar
Atif Zaheer
Adrian Murphy
Nilofer S. Azad
Susan Gearhart
Sandy Fang
Jonathan Efron
Tam Warczynski
Amy Hacker-Prietz
Jeffrey Meyer
spellingShingle Angela Y. Jia
Amol Narang
Bashar Safar
Atif Zaheer
Adrian Murphy
Nilofer S. Azad
Susan Gearhart
Sandy Fang
Jonathan Efron
Tam Warczynski
Amy Hacker-Prietz
Jeffrey Meyer
Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
Radiation Oncology
Rectal cancer
Short-course chemoradiotherapy
Watch and wait
author_facet Angela Y. Jia
Amol Narang
Bashar Safar
Atif Zaheer
Adrian Murphy
Nilofer S. Azad
Susan Gearhart
Sandy Fang
Jonathan Efron
Tam Warczynski
Amy Hacker-Prietz
Jeffrey Meyer
author_sort Angela Y. Jia
title Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
title_short Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
title_full Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
title_fullStr Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
title_full_unstemmed Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
title_sort sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
publisher BMC
series Radiation Oncology
issn 1748-717X
publishDate 2019-08-01
description Abstract Background There is continued debate regarding the optimal combinations of radiation therapy and chemotherapy in the preoperative treatment of locally advanced rectal adenocarcinomas. We report our single-institution experience of feasibility and early oncologic outcomes of short-course preoperative radiation therapy (5 Gy X 5 fractions) followed by consolidation neoadjuvant chemotherapy. Methods We reviewed the records of 26 patients with locally advanced rectal adenocarcinoma. All patients underwent short course radiotherapy (5 Gy X 5 fractions) followed by chemotherapy [either modified infusional and bolus 5-fluorouracail and oxalipatin (mFOLFOX6) or capecitabine and oxaliplatin] prior to consideration for surgery. A full course of chemotherapy was defined as at least 8 weeks of chemotherapy. Results There were five clinical (c) T2, 16 cT3, and five cT4 rectal tumors, with 88% cN+. Twenty-five patients received a median of 4 cycles (range 3 to 8) of mFOLFOX6 (with one cycle defined as a two-week period); one patient received 3 cycles of capecitabine and oxaliplatin. All patients completed SCRT; 81% completed the full course of neoadjuvant chemotherapy with 19% requiring dose reductions in chemotherapy, most commonly due to neuropathy. Nineteen patients underwent post-treatment endoscopic evaluation, and nine patients were noted to achieve a complete clinical response (CCR). Six of the nine patients who achieved CCR opted for a non-operative approach of watch-and-wait. Twenty patients underwent surgical resection; pathologic complete response was observed in seven (35%) of these twenty. The main radiation-associated toxicity was proctitis with CTCAE Grade 2 proctitis observed in seven patients (27%). Post-operative Clavien-Dindo Grade 3 complications within 30 days of surgery were identified in six patients (30%), with no Grade 4 or 5 adverse events. Median length of hospital stay was 4.5 days (range 2–16 days); three patients were readmitted within a 30 day period. Conclusions Short course preoperative radiotherapy followed by neoadjuvant chemotherapy was well-tolerated and achieved oncologic outcomes that compare favorably with short-course radiation therapy alone or long-course chemoradiotherapy. This regimen is associated with high rates of clinical and pathologic complete response.
topic Rectal cancer
Short-course chemoradiotherapy
Watch and wait
url http://link.springer.com/article/10.1186/s13014-019-1358-1
work_keys_str_mv AT angelayjia sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT amolnarang sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT basharsafar sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT atifzaheer sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT adrianmurphy sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT nilofersazad sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT susangearhart sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT sandyfang sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT jonathanefron sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT tamwarczynski sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT amyhackerprietz sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
AT jeffreymeyer sequentialshortcourseradiationtherapyandchemotherapyintheneoadjuvanttreatmentofrectaladenocarcinoma
_version_ 1724473953501577216